
BPC-157
COA published
A synthetic pentadecapeptide studied in in-vitro models of tissue-repair signalling and cellular migration.

Cytoprotective
A combined preparation of BPC-157 and TB-500 used in comparative tissue-repair research models.
Select size
Quantity
Total
$90.00
That's the price. No inflated list, no permanent “discount” code to make it look cheaper than it is.
Batch WB-29053 · Certificate of Analysis available
Have a question?
For research use only. Not for human consumption.
Products supplied by Synthrex Biotech LLC are intended strictly for in-vitro laboratory research and development by qualified professionals. They are not drugs, foods, cosmetics, or dietary supplements, and are not approved by the FDA for human or veterinary use. They are not sold for, and must not be used for, human or animal consumption or administration of any kind. Synthrex Biotech LLC is not a compounding pharmacy or chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, and is not an outsourcing facility as defined under section 503B of that Act. By purchasing, you affirm that you are a qualified researcher acquiring these materials for lawful research purposes only. A Safety Data Sheet (SDS/MSDS) is available on request for every compound.
Sold by Synthrex Biotech LLC. A Safety Data Sheet (SDS) is available on request at support@synthrexbiotech.com.
This is not a distinct molecule with a discovery history of its own. It is a co-formulation of two separately characterised peptides — the gastric pentadecapeptide BPC-157, isolated at the University of Zagreb and described in synthetic form in 1993, and TB-500, a synthetic fragment of thymosin beta-4, whose parent protein was sequenced from bovine thymus in 1981. Each has its own literature; the combination does not.
The two constituents are characterised separately and by different mechanisms: BPC-157 through angiogenic and nitric-oxide signalling in rodent and cell-culture models, thymosin beta-4 through G-actin sequestration and cytoskeletal dynamics in vitro. No peer-reviewed literature characterises this specific co-formulation as a single entity, and no published work establishes an interaction between them. Anything said about the blend is inference from the two component literatures, not a finding about the blend. Neither constituent is FDA-approved for human use, and thymosin beta-4 appears on the WADA Prohibited List. See the individual BPC-157 and TB-500 entries for the primary sources.
These notes are provided for scientific context only. They describe published laboratory and preclinical research and are not a claim of any effect in humans. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Summaries of published literature for research reference only. Not a claim about any product’s effect.
BPC-157 traces back to a question asked at the University of Zagreb in 1975: if the stomach lining survives its own acid, does gastric juice contain something protective? Predrag Sikirić assembled a team in 1981 that collected human gastric juice from hospital gastroenterology clinics and screened the fractions for protective activity. In 1989 the group reported isolating the active fragment, and the synthetic pentadecapeptide was formally described in 1993. It is a 15-amino-acid sequence — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular weight 1419.55 Da — derived from a larger protein found in gastric juice. Unusually for a peptide, it is stable in human gastric juice, which is why the original work was possible at all.
The published literature characterises BPC-157 in animal and in-vitro models as a cytoprotective agent, with reported activity on angiogenic signalling (VEGFR2 pathway), nitric oxide system interaction, and growth-factor expression in gastrointestinal and connective tissue models. The great majority of this work is preclinical — rodent and cell-culture studies. It has not been approved by the FDA for any human use, and human clinical data remains extremely limited.
TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a 43-amino-acid peptide originally isolated from bovine thymus tissue. Its complete amino acid sequence was published in the Proceedings of the National Academy of Sciences in 1981, following work through the 1960s and 70s on biologically active thymus extracts — at that point it was understood as a thymic hormone and studied for its effect on thymocyte populations. The reframing came later, when Tβ4 was identified as a major G-actin sequestering protein. That reclassification, from immune factor to regulator of the cytoskeleton, is the reason the compound appears in tissue-repair literature at all.
Thymosin beta-4 is characterised as a principal G-actin sequestering peptide in mammalian cells: it binds monomeric (G-)actin and influences the balance between free monomer and polymerised filament, which governs cytoskeletal remodelling and cell migration. Later work has examined it as a target of hypoxia-inducible nitric oxide and HIF-1α regulation in cell-culture models. All of this is preclinical and in vitro. TB-500 is not FDA-approved for human use, and thymosin beta-4 is on the WADA Prohibited List.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Summaries of published literature for research reference only. Not a claim about any product’s effect.
Batch releases & restocks
Every certificate is published and available for review. Join the Lab List and we'll tell you when a new one lands and when a sold-out compound is back — plus 15% off your first order, shown on screen the second you join.
Batch and restock notices from Synthrex Biotech LLC. No dosing advice, ever. One-click unsubscribe on every email.

COA published
A synthetic pentadecapeptide studied in in-vitro models of tissue-repair signalling and cellular migration.

COA published
A thymosin beta-4 fragment investigated in research on cellular migration and angiogenesis pathways.

COA pending
A combined BPC-157, GHK-Cu and TB-500 preparation studied in dermal and repair research contexts.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.